Tumor-Initiating and -Propagating Cells: Cells That We Would to Identify and Control  by Tysnes, Berit Bølge
Tumor-Initiating and -Propagating
Cells: Cells That We Would Like
to Identify and Control1
Berit Bølge Tysnes
NorLux Neuro Oncology, Department of Biomedicine,
University of Bergen, Bergen, Norway
Abstract
Identification of the cell types capable of initiating and sustaining growth of the neoplastic clone in vivo is a fun-
damental problem in cancer research. It is likely that tumor growth can be sustained both by rare cancer stem–like
cells and selected aggressive clones and that the nature of the mutations, the cell of origin, and its environment
will contribute to tumor propagation. Genomic instability, suggested as a driving force in tumorigenesis, may be
induced by genetic and epigenetic changes. The feature of self-renewal in stem cells is shared with tumor cells,
and deviant function of the stem cell regulatory networks may, in complex ways, contribute to malignant transfor-
mation and the establishment of a cancer stem cell–like phenotype. Understanding the nature of the more quies-
cent cancer stem–like cells and their niches has the potential to develop novel cancer therapeutic protocols
including pharmacological targeting of self-renewal pathways. Drugs that target cancer-related inflammation
may have the potential to reeducate a tumor-promoting microenvironment. Because most epigenetic modifica-
tions may be reversible, DNA methylation and histone deacetylase inhibitors can be used to induce reexpression
of genes that have been silenced epigenetically. Design of therapies that eliminate cancer stem–like cells without
eliminating normal stem cells will be important. Further insight into the mechanisms by which pluripotency tran-
scription factors (e.g., OCT4, SOX2, and Nanog), polycomb repressive complexes and microRNA balance self-
renewal and differentiation will be essential for our understanding of both embryonic differentiation and human
carcinogenesis and for the development of new treatment strategies.
Neoplasia (2010) 12, 506–515
Introduction
The classic clonal evolution theory where malignant transformation
results from random mutations and subsequent clonal selection and
the cancer stem cell hypothesis arguing that tumor growth is driven
by a rare subpopulation of cells with stem cell–like properties are
continuously discussed as models of carcinogenesis. Recent ad-
vances in stem cell technology and cancer biology have influenced
progress in the understanding of tumor initiation and progression
and elucidated that additional layers outside the DNA can be in-
volved in the regulation of gene expression. However, this knowl-
edge also underlines the heterogeneity and complexity in biology
and response to treatment existing between and within different tu-
mor types. This review focuses on the mechanisms and the cells
involved in tumor initiation and propagation. It aims to mention
aspects related to the debate on tumorigenic potential and mod-
els, to address the regulation of self-renewal and differentiation,
and to point to valuable knowledge that can contribute to new ther-
apeutic strategies.
Tumor Initiation—Mechanisms and Cell
Types Involved
The cellular origin of the cancer-initiating cell has been focused and
debated for more than 100 years. Cancer, as a heterogeneous group
of disorders with marked different biologic properties, is thought to
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arise from a single cell, where series of genetic alterations in tumor-sup-
pressor genes and oncogenes are responsible for continued clonal selec-
tion and tumor cell heterogeneity, resulting in tumor proliferation,
invasion, metastasis, and drug resistance [1].
The clonal genetic model of cancer has been successful in predict-
ing mutations that seem to be necessary for the earliest stages of tu-
mor growth. However, pathologic epigenetic changes (changes in
gene expression that do not involve a change in DNA sequence)
are increasingly considered as alternatives to mutations and chromo-
somal alterations in disrupting gene function [2]. Genomic instabil-
ity has been suggested as a driving force in tumorigenesis [3,4]. There
are, however, indications that epigenetic changes such as global DNA
hypomethylation and promoter-specific hypermethylation can be
early events in the loss of cellular homeostasis and may precede genetic
mutations and genomic instability in some instances [5]. Genetic in-
stability may be induced by deregulated epigenetic mechanisms and
then result in the acquisition of genetic mutations that can induce si-
lencing of tumor-suppressor genes and activation of oncogenes. Chro-
mosomal instability generation, reactivation of transposable elements,
and loss of imprinting are proposed mechanisms of how DNA hypo-
methylation can contribute to cancer development [5].
Several epigenetic mechanisms such as DNA methylation, histone
modification, and microRNA expression may change the genome
function through both endogenous and environmental factors [6–8].
MicroRNA (single-stranded noncoding RNA molecules of 20-22
nucleotides) are now known to have a central role in the regulation
of gene expression and to be implicated in an increasing number of
biologic processes (reviewed in Bartel [9], He and Hannon [10], and
Zhang et al. [11]). They are important in developmental processes,
including differentiation, proliferation, and apoptosis [12]. Expres-
sion of microRNA is frequently decreased or increased in cancerous
tissues, and many microRNA are located at or close to genomic sites
that are commonly deleted or amplified in various cancers [13].
There are also reports indicating that altered expressions of specific
microRNA genes contribute to the initiation and progression of
cancer [14,15]. Profiles of microRNA expression are shown to dif-
fer between normal tissues and tumor tissues and among tumor
types [14–19].
Infection, Inflammation, and Tissue Repair
Infection, inflammation, and tissue repair processes are increas-
ingly recognized as important factors that may contribute to tumor
development [20–24]. Interestingly, cancer-related inflammation is
suggested to contribute to genetic instability in tumor cells. Inflam-
matory mediators may by a variety of mechanisms influence DNA
repair pathways and thereby induce microsatellite instability. Such
mediators may also induce double-strand breaks, defective mitotic
checkpoint, and deregulated homologous recombination leading to
chromosomal instability [25]. An uncontrolled “wound-healing pro-
cess” during tissue repair might possibly attract and/or initiate mesen-
chymal stem cells or other cells resulting in stimulated or deregulated
self-renewal processes. In this context, cell fusion and/or horizontal
gene transfer events may play a role [26,27].
Cell Properties
The multistep tumorigenesis theory focuses on the nature and
number of mutations rather than on the properties of the cell in
which they occur. Identification of the cell types capable of initiating
and sustaining growth of the neoplastic clone in vivo is a fundamental
problem in cancer research.
A tumor can be viewed as an aberrant organ initiated by a tumor-
igenic cancer cell that has acquired the capacity for indefinite prolif-
eration through accumulated mutations. The balance between cell
proliferation, differentiation, and apoptosis has influence on the total
amount of cells in the body. An aberrant regulation of these processes
can induce cancer development. During development, cellular differ-
entiation of the unspecialized pluripotent embryonic stem cells in the
inner mass of early embryos occurs. All tissues in the body are de-
rived from organ-specific stem cells that are defined by their capacity
to undergo self-renewal as well as to differentiate into the cell types
that comprise each organ. These tissue-specific stem cells are distin-
guished from embryonic stem cells in that their differentiation is
largely restricted to cell types within a particular organ. There are also
adult stem cells that are involved in the regeneration of tissues during
the lifetime of the individual. Some stem cells are continuously active
to replace cells as they mature and die off as, for instance, skin cells.
Other stem cells remain dormant until a physiological signal is received;
for example, some breast stem cells respond strongly to pregnancy hor-
mones and, to a lesser extent, to hormones within the monthly cycle. It
has becomemore andmore evident that normal development and can-
cer share many properties. The feature of self-renewal in stem cells is
shared with tumor cells, and this common property has led to the pro-
posal that self-renewal provides increased opportunities for carcinogenic
changes to occur. It has also been suggested that altered regulation
of self-renewal directly underlies carcinogenesis [28]. Stem cells live
longer than many differentiated cells and may therefore be exposed
to damaging agents for a longer time, allowing accumulation of mu-
tations that can result in transformation [29,30].
Cancer Stem Cell Hypothesis
That cancer might arise from a rare population of cells with stem
cell properties was proposed approximately 150 years ago (references
in Wicha et al. [31]). It has been also more than 40 years since tissue-
specific stem cells were postulated to be the cell of origin in cancer
[32]. The concept of a less differentiated, more pluripotent cell form-
ing cancer was taken a step further when it was proposed that cancers
represented a maturation arrest of stem cells [33]. Development of
fluorescence-activated cell sorting, recent advances in stem cell biol-
ogy, and the development of new xenotransplantation animal mod-
els have improved the possibilities to validate the cancer stem cell
hypothesis, stating that only a minority of cells within a tumor are
responsible for tumor initiation and maintenance. During the last
years, it has been possible to isolate and characterize these cells from
hematological malignancies [34,35] based on the use of markers that
are thought to distinguish tumorigenic from nontumorigenic cells. A
number of recent articles have reported that cancer stem cells can also
be isolated from solid human cancers such as breast, brain, bone, lung,
melanomas, prostate, colon, pancreas, liver, and head and neck [36–48].
The term cancer stem cell is still an operational term defined as a
cancer cell that has the ability to self-renew to give rise to another ma-
lignant stem cell as well as a cell that will give rise to the phenotypic
diverse cancer cells that are known as transient amplifying cells
[31,49–51]. The transient amplifying cells are believed to be the
cells that are responsible for the bulk tumor cell proliferation that is
responsive to conventional therapy, whereas the cancer stem–like cells
can be left intact and will eventually repopulate the tumor [51,52]
(Figure 1).
Neoplasia Vol. 12, No. 7, 2010 Tumor Initiating and Propagating Cells Tysnes 507
Traditionally, many cancer cells have been considered to have tu-
morigenic potential, but the cancer stem cell model has suggested
that only small subpopulations of cancer cells have tumorigenic po-
tential based on experiments in which human cancer cells were trans-
planted into nonobese diabetic/severe combined immunodeficiency
(NOD/SCID) mice [34,35]. Although xenotransplantation animal
models have improved the possibility to study the cancer stem cell
hypothesis, the critical role of tumor growth interactions with the
local and extended microenvironment complicates the interpretation
of such studies. An alternative explanation of the low frequency of
tumor-producing cells from, for example, human acute myeloid leu-
kemia (AML) in NOD/SCID mice may be that these rare tumor cells
are the cells that can adapt to growth in a foreign environment [53].
Xenotransplantation may therefore fail to reveal several growth-
sustaining cells because the foreign microenvironment hinder essential
interactions with human support cell such as fibroblasts, endothelial
cells, macrophages, mast cells, and mesenchymal stem cells [54].
The nontransplantable human AML cell populations may lack critical
features for obtaining stromal support, for instance, through cytokine
and chemokine factors and receptors in the foreign microenviron-
ment, whereas the transplantable population may have acquired fea-
tures that enable those cells to survive in a foreign milieu. There are
also concerns whether the lack of an appropriate microenvironment
of xenografts in the immunocompromised mouse models underesti-
mates the frequency of tumor-initiating and -sustaining cells. Such fre-
quencies may best be tested by transferring mouse tumor cells into
nonirradiated histocompatible recipient mice [53]. This is underlined
by the recent report by Kelly et al. where they show that a large pro-
portion of murine lymphoid and myeloid tumors in syngeneic mouse
tumor models were able to initiate tumor formation.
The role of the microenvironment in the development of solid tu-
mors are thought to be even more complex than that of hematopoi-
etic cancers because solid tumors are challenged by tissue barriers and
the need for angiogenesis (for review, see Visvader and Lindeman
[55]). The differentiation pathways in such tumors are also less well
understood. However, Quintana et al. [56] have shown that, by modi-
fying xenotransplantation assay conditions, including the use of more
highly immunocompromised mice, they can increase the detection of
tumorigenic melanoma cells by several orders of magnitude. Such
studies indicate that cells with tumorigenic potential are likely to be
much more frequent in many human cancers than estimates based on
pure xenotransplantations. These studies also indicate that the immune
system may play a role in the selective growth of tumor-initiating cells.
Whether cells with tumorigenic potential are common or rare
within human cancers is still a fundamental question in cancer bio-
logy. The degree to which the cancer stem cell and clonal evolution
models are mutually exclusive and whether a single cancer stem cell
hierarchy exists in patients with cancer also remain open questions
Figure 1. Schematic illustration of development of tumor tissue compared to normal tissue and the potential therapeutic window of
traditional chemotherapeutic agents in different cell populations. The stem cell compartment is thought to accommodate cells with a
low proliferation rate, high tumorigenic capability, and increased DNA repair capacity. Thus, the chemotherapeutic efficacy is believed to
be smaller in this subpopulation compared to cells from the bulk tumor mass. Although these bulk tumor cells may better respond to
chemotherapy, the tumor mass might still contain quiescent or active cancer stem–like cells with self-renewal and tumorigenic capacity
that can be difficult to eliminate with conventional chemotherapeutic drugs alone.
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[57]. Although the cancer-initiating cells are still not fully identified
or characterized, they seem to display different phenotypes, which
can possibly be derived from both embryonic and adult stem cell
pools, as well as from progenitor or differentiated cells [26]. Evidence
for tumor initiation from embryonic stem cells is revealed from stud-
ies showing that transplantation of undifferentiated human embry-
onic stem cells into immunodeficient mice form teratomas, large
tumor-like formations containing tissues belonging to all three germ
layers [58]. Teratomas can also appear spontaneously in mice and hu-
mans and are defined as teratocarcinomas when they contain a core
of malignant undifferentiated cells [59]. Evidence from leukemia
suggests that cancers can be initiated from multiple cell types in de-
velopmental hierarchies [60].
Tumor growth can most likely be sustained either by rare cancer
stem–like cells or by selected aggressive clones or both, and the na-
ture of the mutations, the cell of origin, and its environment can also
contribute to tumor propagation. Tumors may be initiated in a way
that follows the stem cell paradigm and further progress to acquire
additional mutations that resemble the clonal evolution model. Such
tumors could then exhibit features of both models [54,55]. Stem-like
cells in a hierarchical organized tumor are not necessarily static, and
multiple clones of stem-like cells may evolve in response to treatment
and changes in the microenvironment. There are no clear-cut answers,
and events from several models are most likely involved during cancer
development and propagation. Proving or disproving a single specific
hypothesis or model will probably not provide the best basis for new
generation of successful therapies.
Tumor-Initiating versus Tumor-Propagating Cells
Distinction between the cells that give rise to the first form of the
tumor, which may be stem cells, progenitor cells, or differentiated
cells depending on the tumor phenotype, and cells that propagate
the tumor and exhibit self-renewal and differentiation capacity would
be of great value [61]. There are, however, several challenges for es-
tablishing such a distinction. For example, recent studies have shown
that CD133, previously thought to be a robust brain tumor stem cell
marker [39,62], does not consistently distinguish tumorigenic from
nontumorigenic cells [63–66]. The CD133 has also been used as a
phenotypic marker of colon cancer stem cells [44,45], but also in this
cancer type, both CD133-negative and -positive populations have
been reported to induce tumor growth in vivo [67]. The markers used
to isolate stem cells in normal and cancerous tissues are not expressed
exclusively by stem cells. Neither can markers used for identification
of stem cells in one organ directly be used for identification in other
organs. Such conditions underline the importance of linking pheno-
typic markers with functional assays. The activity of aldehyde dehy-
drogenase isoform 1 that can be assessed by the ALDEFLUOR assay
has been identified as a common functional marker of normal and
malignant human breast stem cells [68]. Aldehyde dehydrogenase iso-
form is also expressed in hematopoietic, neuronal, and colonic stem
cells, and aldehyde dehydrogenase isoform 1 may have a promising
potential as a universal functional marker for identification and isola-
tion of stem cells from multiple sources [69,70]. CD44 and CD133
have been reported as cell surface cancer stem cell markers in several
solid tumor types [71]. Interestingly, it has recently been reported that
CD44, in contrast to CD133, seems to be a robust marker of func-
tional importance for colorectal cancer initiation [72].
Cell plasticity properties such as epithelial-to-mesenchymal transi-
tions (EMT) also threat the identification of tumor-initiating cells.
During development, multicellular organisms are dependent on the
EMTof polarized epithelial cells to motile cells. Interactions between
epithelial cells and mesenchymal cells with a migratory morphology
are essential in organ formation, and such transitions can also be
activated during cancer invasion and metastasis (for review, Thiery
et al. [73]). Recently, EMT has been reported to generate cells with
stem cell–like properties [74,75].
Regulation of Self-renewal and Differentiation
Disruption of genes and pathways involved in the regulation of
stem cell self-renewal seems to be important in the stem cell model
of cancer [27–29,76–79]. Whether stem cells or cancer stem–like
cells continue to self-renew or start to undergo differentiation is
thought to be influenced by the microenvironment [55,80,81]. It
has been suggested that cancer can be initiated by a loss of polarity
in stem cells that may lead to impairment of asymmetric cell division,
rendering the daughter cells unable to respond to normal homeostasis
mechanisms that regulate cell proliferation [82]. Interestingly, recent
data demonstrate that the tumor-suppressor p53 regulates polarity of
self-renewing divisions in mammary stem cells and suggest that loss of
p53 favors symmetric divisions of cancer stem–like cells contributing
to tumor growth in a transgenic model of breast cancer [83].
An emerging role of microRNA in the regulation of stem cell self-
renewal and differentiation [12,84] has been revealed, indicating that
they are crucial for proper stem cell function and maintenance. Dur-
ing development, microRNA expression seems to be tissue specific,
and this may implicate that microRNA are essential to establish and
maintain cell type and tissue identity [85,86]. Coordinated transcrip-
tion factor networks involving OCT4, SOX2, and Nanog have cur-
rently emerged as the master regulatory mechanisms of stem cell
pluripotency and differentiation [87], and microRNA to OCT4,
SOX2, and Nanog coding regions are found to modulate embryonic
stem cell differentiation [88]. Interestingly, miR-302 that can target
OCT4/SOX2/NANOG has been shown to have a role in converting
differentiated cells to induced pluripotent stem cells [89,90]. MiRNA
loci and promoter regions related to pluripotency and self-renewal reg-
ulating transcription factors are shown in Table 1. Knowledge of pre-
dicted microRNA that target different regulators of pluripotency can
be of value in the design of future experimental studies (knockout/
Table 1. MicroRNA Associated with Transcription Factors Regulating Pluripotency and Self-
renewal in Embryonic Stem Cells.
miRNA Loci Near OCT4/SOX2/NANOG
Bound Regions in Human Embryonic
Stem Cells [91]
miRNA Promoter Regions Binding to
OCT4/SOX2/NANOG/TCF3 in Human
and Mouse Embryonic Stem Cells [92]
miR-137 (OSN) miR-302 cluster
miR-301 (OSN) miR-290/371 cluster
miR-22 (SN) miR-363 cluster
miR-32 (SN) miR-148/152
miR135b (SN) miR-135b
miR-204 (SN) miR-124
miR-205(SN) miR-615
miR-10a (O) miR-708
miR-196b (O) miR-9
miR-448 (O)
miR-7-1 (S)
miR-128a (N)
miR-196a-1 (N)
miR-361 (N)
O indicates OCT4; S, SOX2; N, NANOG.
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knockdown/overexpression) to gain insight and target master regula-
tors of pluripotency (Table 2). Available experimental data related to
microRNA and pluripotency genes (Table 3) reveal biologic knowl-
edge and basis for interfering with pluripotency, self-renewal, and dif-
ferentiation by microRNA.
It has been hypothesized [99] that several microRNA associated
with glioblastomas may have a normal function in regulating neural
stem cell self-renewal and differentiation during development. How-
ever, their dysfunction in cancer may contribute to the maintenance
of an undifferentiated proliferative phenotype by preventing the ex-
pression of differentiation targets and allowing the expression of tar-
gets promoting stem cell renewal [18,19].
There are still challenges with respect to identification and con-
trol of tumor initiating and propagating cells. Increased mechanistic
knowledge of the cellular processes that establish and/or maintain
such cells is needed. Embryonic stem cells are known to rely on poly-
comb group proteins to reversibly repress genes required for differen-
tiation [100]. Interestingly, it has been hypothesized that acquisition
of promoter DNA methylation at these repressed genes could perma-
nently silence them and thereby lock the cell into a perpetual state of
self-renewal [101–103] predisposing to subsequent malignant trans-
formation and cancer development. Epigenetic repressive pathways
involving polycomb complexes, DNA methylation, and microRNA
seem to cooperate to reduce transcriptional noise and to prevent aber-
rant induction of differentiation. Deviant function of the stem cell
regulatory network may therefore, in complex ways, contribute to ma-
lignant transformation and the establishment of a cancer stem cell–like
phenotype [87].
Treatment
A key challenge in cancer biology is to target the most aggressive tumor
cells within a cancer. Opinions of how many and which tumor cells
must be eliminated for cancer treatment to be successful are divided.
Depending on the circumstances, there are now reports supporting
both the perspectives that every tumor cell can propagate human can-
cer and that this property is exclusive to a subpopulation of particular
cells [104]. Effective therapy will probably require targeting of all
the tumor cell populations by combinational approaches [54], and a
deeper understanding of tumor-initiating and -propagating mecha-
nisms is therefore required. For safety, the goal for any therapy should
be the elimination of all malignant cells because of their potential to
expand to form tumors and to disseminate [105]. Increasing evidence
suggests that nonmalignant host cell populations play a significant role
in tumor growth, indicating requirements for a better understanding
of how to target effects on tumor initiation and propagation also from
these cells [24]. Drugs that, for instance, target cancer-related inflam-
mationmay have the potential to reeducate a tumor-promoting micro-
environment to become a tumor-inhibiting environment [106].
Cytokine networks play important roles in tumorigenesis, and there
is also evidence that cytokines may regulate stem cell behavior. Colon
carcinoma stem–like cells identified by expression of the cell surface
marker CD133 are found to produce and use interleukin 4 (IL-4) in
apoptosis protection [107]. Treatment with inhibitors of IL-4 revealed
enhanced antitumor chemotherapy efficacy through selective sensiti-
zation of the CD133-positive cells. IL-6 can induce malignant prop-
erties in breast cancer stem–like cells by triggering the Notch pathway
[108], and the up-regulation of IL-6 is indicated as a possible inflam-
matory or hypoxia stress response. Charafe-Jauffret et al. [109] used
Table 2. Predicted microRNA Targeting Master Regulators of Pluripotency and Differentiation
(TargetScan, Release 5.1, 2009) [93,94].
Gene Conserved among Vertebrates Poorly Conserved Selected
(Context Score Percentile >80)
Human (hsa)
OCT4 (POUF1) miR-335 miR-595
miR-892a miR-486-5p
miR-299-3p
miR-412
miR-452
miR-1257
miR-508-5p
SOX2 miR-429 None
miR-200c
miR-200b
NANOG miR-1293 miR-579
miR-720
miR-526b
miR-198
miR-128
miR-548
miR-1273
miR-766
miR-940
miR-769-5p
miR-548n
miR-548l
miR-567
miR-520d-5p
miR-1298
miR-643
miR-199a-5p
miR-150
miR-553
miR-765
miR-575
Mouse (mmu)
OCT4 miR-881 miR-218
miR-679
miR-324-5p
SOX2 miR-200b None
miR-429
miR-200c
NANOG None miR-763
Table 3. MicroRNATargeting Master Regulators of Pluripotency and Differentiation (Experimen-
tal Data).
miRNA Target Expression/Function
miR-145 OCT4 Low expression in self-renewing hESCs and upregulated
during differentiation. Represses self-renewal and
pluripotency and controls differentiation in hESCs [95].
SOX2
KLF4
miR-302 cluster OCT4 Abundantly expressed in slow-growing hESCs. Decreased
expression after differentiation and proliferation [96].
Upregulated in induced pluripotent stem cells [90].
miR-302 transfection functions to reprogram cancer
cells into an embryonic stem cell–like pluripotent state
expressing markers as OCT4, SSEA-4, SOX2, and
NANOG [89]. OCT4 and SOX2 required for
transcriptional regulation of miR-302a in hESCs.
miR-302 involved in cell cycle regulation in hESCs.
OCT4 and miR-302 expression reduced after retinoic
acid–induced differentiation [97].
SOX2
NANOG
miR-134/296/470 OCT4 Upregulated on retinoic acid–induced differentiation of
mouse embryonic stem cells [88].SOX2
NANOG
miR-21 Suppresses self-renewal of mouse embryonic stem cells,
corresponding to decreased expression of Oct4, Nanog,
Sox2, and c-Myc [98].
hESC indicates human embryonic stem cell.
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the ALDEFLUOR assay to isolate cancer stem cell populations from
normal and malignant mammary tissues. Increased expression of
CXR1/IL-8RA was revealed by oligonucleotide microarray in the
ALDEFLUOR-positive population. Furthermore, recombinant IL-8
was found to increase the expression of ALDEFLUOR-positive cells
and the tumor sphere–forming capacity in breast cancer cell lines. In-
terestingly, it has also recently been reported that breast cancer stem–
like cells can be targeted and selectively decreased through blockage
of the IL-8 receptor CXCR1 in vitro and in NOD/SCID xenograft
models [110].
Targeting proteins involved in EMTmay also be an option to include
in the therapeutic strategy to eliminate detrimental cells [73,111] be-
cause chemoresistance in tumors undergoing EMT has been indicated
[112] and depletion of the EMT-inducing transcription factor Twist1
improve chemotherapy efficacy in breast cancer cells [113].
The concept of cancer stem–like cells has significant clinical impli-
cations as cancer stem–like cells are thought to be more resistant to
chemotherapy and radiotherapy. Increased drug efflux, metabolic al-
terations, cell cycle kinetics, and enhanced DNA repair as well as
deregulated differentiation are suggested to be involved [114–119].
Understanding the nature of the more quiescent cancer stem–like cells
and their niches has the potential for the development of novel cancer
therapeutic protocols [120]. The elucidation of self-renewal pathways
has already identified some novel pharmacological targets, and novel
compounds are being developed with preclinical activity and hope for
clinical utility [121–124]. Recently, an approach to identify selective
inhibitors of cancer stem cells by high-throughput screening has been
described [125]. Furthermore, low proteasome activity has been sug-
gested as a general feature of cancer-initiating cells, which can be
exploited to identify and target such cells both in vitro and in vivo
[126]. Cancer stem cell–directed therapeutic approaches to target
stem-like cells in different organ-specific tumors has been suggested
as relevant strategies to improve clinical cancer therapy (overview in
Schatton et al. [71], Frank et al. [127], and Winquist et al. [128]). A
recent study [52] shows the importance of specifically targeting the tu-
morigenic population of breast cancer cells. Conventional chemother-
apy in a neoadjuvant setting to both HER2-positive and -negative
human tumors was found to increase the proportion of a highly tumor-
igenic subpopulation (CD44+/CD24−) of breast cancer cells. In con-
trast, after the more specific targeted treatment of HER2-positive
tumors with the epidermal growth factor receptor/HER2 inhibitor
lapatinib, no increase in the tumorigenic subpopulation in the biopsy
samples was found. The study underlines that targeting both tumori-
genic and dividing daughter cells is essential in preventing cancer re-
lapse (Figure 1).
CD133-positive glioma cells with tumor-initiating properties have
been reported to promote radioresistance by preferential activation of
DNA damage response [129]. This resistance was reversed with spe-
cific inhibitors of Chk1 and Chk2 checkpoint kinases. Furthermore,
Notch signaling that is involved in self-renewal regulation and stem
cell fate determination was also found to be important in the regu-
lation of radioresistance of such cells [130]. The Notch promoted
radioresistance was indicated to be regulated through activation of dif-
ferent cellular survival mechanisms as the phosphatidylinositol-3-OH
kinase/Akt pathway and up-regulation of prosurvival proteins and also
through p53 interaction. Tumor-initiating cells from p53 null mouse
mammary tumors have also recently been shown to repair radiation-
induced DNA damage more efficiently than the tumor bulk cells
[131]. Down-regulation of PTEN (phosphatase and tensin homolog
deleted on chromosome 10) increased Akt signaling, and activation of
the canonical Wnt/β-catenin signaling pathway was observed in these
cells. Furthermore, by pharmacological inhibition of the Akt pathway,
Wnt signaling andDNAdamage repair were inhibited, and the tumor-
initiating cells were sensitized to radiation.
Hypoxia is also known to play a role in tumor radioresistance, and
local tumor control after radiotherapy is found inversely correlated
with tumor hypoxia. In that connection, it has been suggested that
hypoxia might affect stem cell generation and maintenance in tumors
through activation of hypoxia-inducible factors (HIFs) [132]. Inter-
estingly, activation of HIF-2α may induce the expression of OCT4,
and HIF-1α can interact with Notch signaling and thereby contribute
to the maintenance of an undifferentiated cell state [133–135].
Induction of differentiation of cancer stem–like cells by different
methods is suggested as a potential treatment strategy. For instance
has bone morphogenic proteins been reported to inhibit tumorigenic
potential of brain tumor–initiating cells by triggering Smad signaling,
reducing proliferation, and promoting differentiation [136]. Epige-
netic therapy is suggested as a potential strategy to induce differentia-
tion of cancer stem–like cells [137–139]. In contrast to geneticmutations,
most epigenetic modifications may be reversible and preventable, and
this knowledge expands the therapeutic possibilities. The findings that
epigenetic mechanisms such as DNA methylation and histone modi-
fications can affect gene expression enable the potential to interfere
with gene expression by the use of pharmacologicals as DNA methyl-
ation and histone deacetylase inhibitors to induce reexpression of
genes that have been silenced epigenetically. DNA methylation and
histone deacetylase inhibitors have been used both in preclinical and
in clinical studies [140,141], and combined treatment strategies are, in
some cancers, shown to be more effective than individual treatment
approaches [142–144].
Given that microRNA regulate gene expression and easily enter the
cell, they may also have a therapeutic potential against cancer [145].
The recent demonstration that human breast cancer stem–like cells
compared with nontumorigenic cancer cells differentially express a
microRNA cluster that specifically targets BMI1, a critical promoter
of stem cell self-renewal belonging to the polycomb group complex,
indicates the potential to target self-renewal and differentiation reg-
ulation in cancer stem–like cells by microRNA [146]. The fact that
many microRNA are expressed at low levels in tumors but at high
levels in normal tissues indicates possibilities for differential targeting
and that they can be tolerated in normal cells [145].
The similarity of cancer stem–like cells to normal stem cells indi-
cates that they inherit or acquire stem cell properties. An important
question is whether it will be possible to identify therapies that elimi-
nate cancer stem–like cells without eliminating normal stem cells in the
same tissues to avoid intolerable adverse effects. Recent reports suggest
that cancer stem–like cells can be selectively targeted without altering
normal stem cell function. PTEN is a phosphatase that attenuates pro-
liferation and survival signals through the negative regulation of the
phosphatidylinositol-3-OH kinase pathway. It is a frequently mutated
gene in human cancers and can be inactivated by different mechanisms
[147,148]. Alterations in the PTEN pathway are associated with leu-
kemogenesis, and it has been shown that PTEN plays a critical role in
controlling hematopoietic stem cell proliferation and differentiation
[149]. Yilmaz et al. [150] have shown that PTEN deletion causes gen-
eration of transplantable leukemia-initiating cells but also depletion of
normal hematopoietic stem cells; however, there seems to be a mech-
anistic difference between the maintenance of normal stem cells and
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leukemia-initiating cells. These studies indicate that compounds that
promote stem cell quiescence might have different effects on normal
stem cells and cancer stem–like cells and that it can be possible to iden-
tify and target pathways that have distinct effects on normal stem cells
and cancer stem–like cells within the same tissue. Another example of
potentially targeting cancer stem–like cells specifically is provided by
recent studies showing that embryonic carcinoma cells exhibit a higher
sensitivity to the histone deacetylase inhibitor apicidin compared with
embryonic stem cells in down-regulation of Nanog, which is likely to
act as a master transcription regulator controlling pluripotency [151].
Conclusions
The acquisition and maintenance of cell fate or “identity” regulated by
a strict coordination between genetic and epigenetic programs are es-
sential for growth and development. Cancer cells possess traits remi-
niscent of those ascribed to normal stem cells. It has been shown that
histologically poorly differentiated tumors show preferential over-
expression of genes normally enriched in embryonic stem cells com-
bined with repression of polycomb-regulated genes and overexpression
of activation targets of Nanog, OCT4, SOX2, and c-Myc [152]. In
this way, poorly differentiated aggressive tumors show an embryonic
stem cell–like gene expression signature. An epigenetic stem cell signa-
ture showing DNA promoter hypermethylation of polycomb group
targets has also been found in human colorectal tumors as well as in
ovarian and breast cancers [103]. These findings reveal that under-
standing the mechanisms by which pluripotency transcription factors,
polycomb repressive complexes, and microRNA balance between self-
renewal and cellular proliferation and differentiation is essential for our
understanding of both embryonic differentiation and human carcino-
genesis [87,92,153] (Figure 2).
Assembly of available and future knowledge should pave the way for
increased understanding and development of multifaceted approaches
of ex vivo and in vivomodels, leading to further characterization of the
cancer-initiating and -propagating cells and their niches. Such knowl-
edge should also lead to possibilities to decipher chemoresistance and
treatment sensitivity mechanisms and to development of more effi-
cient therapy.
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